Zydus Cadila Begins Clinical Development of H1N1 Vaccine

Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for an H1N1 vaccine following an approval by the Drug Controller General of India. The company says it is the first Indian company authorized to begin trials for the H1N1 vaccine.

The egg-based vaccine is expected to be available by April 2010. The company estimates that demand for the H1N1 vaccine in India will be 50–60 million does in the initial phase.